Patents by Inventor Rinpei Niwa
Rinpei Niwa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240059788Abstract: The purpose of the present invention is to provide a bispecific antibody containing an antigen-binding domain which binds to CD40 and an antigen-binding domain which binds to the Epithelial Cell Adhesion Molecule (EpCAM). This invention pertains to a bispecific antibody containing an antigen-5 binding domain which binds to CD40 and an antigen-binding domain which binds to EpCAM.Type: ApplicationFiled: August 21, 2023Publication date: February 22, 2024Applicant: Kyowa Kirin Co., Ltd.Inventors: Makoto Nakayama, Nobuaki Takahashi, Sayaka Maeda, Rinpei Niwa
-
Publication number: 20230406926Abstract: An object of the present invention is to provide a bispecific antibody that binds to CD3 or a bispecific antibody fragment thereof. The present invention relates to a bispecific antibody that binds to CD3 or a bispecific antibody fragment thereof, a DNA encoding the bispecific antibody or the bispecific antibody fragment thereof, a vector containing the DNA, a hybridoma and a transformant that produce the bispecific antibody or the bispecific antibody fragment thereof, a method for producing the bispecific antibody or the bispecific antibody fragment thereof, therapeutic and diagnostic agents containing the bispecific antibody or the bispecific antibody fragment thereof, therapeutic and diagnostic methods using the bispecific antibody or the bispecific antibody fragment thereof, and a reagent for detection or measurement containing the bispecific antibody or the bispecific antibody fragment thereof.Type: ApplicationFiled: February 12, 2021Publication date: December 21, 2023Applicant: Kyowa Kirin Co., Ltd.Inventors: Rinpei NIWA, Shinya OGAWA, Mami WAJIMA, Tsuguo KUBOTA
-
Patent number: 11773180Abstract: An object of the present invention is to provide a bispecific antibody comprising an antigen-binding domain that binds to CD40 and an antigen-binding domain that binds to an epithelial cell adhesion molecule (EpCAM). The present invention relates to a bispecific antibody comprising an antigen-binding domain that binds to CD40 and an antigen-binding domain that binds to EpCAM.Type: GrantFiled: November 6, 2018Date of Patent: October 3, 2023Assignee: KYOWA KIRIN CO., LTD.Inventors: Makoto Nakayama, Nobuaki Takahashi, Sayaka Maeda, Rinpei Niwa
-
Publication number: 20230159662Abstract: An object of the present invention is to provide an antibody composition, which exhibits an effector function more specifically for a target cell coexpressing two types of antigens that are different from each other and damages the target cell, and also can maintain affinity for the individual target antigens sufficiently high. The present invention relates to an antibody composition against a first antigen and a second antigen that are different from each other, including a first IgG half-molecule and a second IgG half-molecule and relates to the first IgG half-molecule and the second IgG half-molecule constituting the antibody composition.Type: ApplicationFiled: April 1, 2021Publication date: May 25, 2023Applicant: Kyowa Kirin Co., Ltd.Inventors: Rinpei NIWA, Katsuaki USAMI
-
Publication number: 20210380684Abstract: An object of the present invention is to provide an antibody composition, which more selectively exhibits an effector function against a target cell coexpressing two types of antigens that are different from each other and damages the target cell, and also can maintain affinity for the individual target antigens sufficiently high. The present invention relates to an antibody composition against a first antigen and a second antigen that are different from each other, composed of a first IgG half-molecule and a second IgG half-molecule.Type: ApplicationFiled: September 27, 2019Publication date: December 9, 2021Applicant: Kyowa Kirin Co., Ltd.Inventors: Rinpei NIWA, Katsuaki USAMI
-
Publication number: 20210380713Abstract: An object of the present invention is to provide a bispecific antibody comprising an antigen-binding domain that binds to CD40 and an antigen-binding domain that binds to an epithelial cell adhesion molecule (EpCAM). The present invention relates to a bispecific antibody comprising an antigen-binding domain that binds to CD40 and an antigen-binding domain that binds to EpCAM.Type: ApplicationFiled: November 6, 2018Publication date: December 9, 2021Applicant: Kyowa Kirin Co., Ltd.Inventors: Makoto NAKAYAMA, Nobuaki TAKAHASHI, Sayaka MAEDA, Rinpei NIWA
-
Patent number: 10494437Abstract: According to the present invention, a heterodimer protein composition that is composed of a first polypeptide comprising an immunoglobulin heavy chain constant region and a second polypeptide comprising CL-Fc prepared by fusion of an immunoglobulin light chain constant region (CL) and Fc region, and also has a deletion or substitution of Cys residues involved in disulfide bonds between CL and CH1, a purification method of the protein composition thereof, a preparation method of the protein composition thereof, a DNA and a vector encoding the protein composition thereof are provided.Type: GrantFiled: June 15, 2017Date of Patent: December 3, 2019Assignee: KYOWA KIRIN CO., LTDInventors: Rinpei Niwa, Mami Tsuchiya, Takuya Murakami, Yuta Tezuka
-
Patent number: 10040861Abstract: Among N-glycoside-linked sugar chains which are bound to the Fc region of an antibody, sugar chains which are bound to Asn at position 297 relates to the activity and stability of the antibody in blood, but there is a possibility that extra sugar chains bound to the amino acid residues at positions other than 297 have influences upon the antibody constant region-mediated activity and a possibility of causing a problem of uniformity as a therapeutic antibody preparation. Accordingly, among N-glycoside-linked sugar chains which bind to the Fc region of the antibody, a method for controlling extra sugar chains which are bound to Asn residues at positions other than position 297 according to the EU index is required.Type: GrantFiled: December 16, 2016Date of Patent: August 7, 2018Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Rinpei Niwa, Mami Tsuchiya
-
Publication number: 20170362323Abstract: According to the present invention, a heterodimer protein composition that is composed of a first polypeptide comprising an immunoglobulin heavy chain constant region and a second polypeptide comprising CL-Fc prepared by fusion of an immunoglobulin light chain constant region (CL) and Fc region, and also has a deletion or substitution of Cys residues involved in disulfide bonds between CL and CH1, a purification method of the protein composition thereof, a preparation method of the protein composition thereof, a DNA and a vector encoding the protein composition thereof are providedType: ApplicationFiled: June 15, 2017Publication date: December 21, 2017Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Rinpei NIWA, Mami TSUCHIYA, Takuya MURAKAMI, Yuta TEZUKA
-
Patent number: 9714291Abstract: According to the present invention, a heterodimer protein composition that is composed of a first polypeptide comprising an immunoglobulin heavy chain constant region and a second polypeptide comprising CL-Fc prepared by fusion of an immunoglobulin light chain constant region (CL) and Fc region, and also has a deletion or substitution of Cys residues involved in disulfide bonds between CL and CH1, a purification method of the protein composition thereof, a preparation method of the protein composition thereof, a DNA and a vector encoding the protein composition thereof are provided.Type: GrantFiled: October 4, 2013Date of Patent: July 25, 2017Assignee: KYOWA HAKKO KIRIN CO., LTDInventors: Rinpei Niwa, Mami Tsuchiya, Takuya Murakami, Yuta Tezuka
-
Publication number: 20170190781Abstract: According to the present invention, anti-death receptor 3 (DR3) antagonistic IgG antibodies and antibody fragments thereof, wherein the antibodies and the antibody fragments thereof display a decreased agonistic activity or no agonistic activity for DR3 through their binding, an antibody compositions and an antibody fragment compositions comprising them, a nucleotide sequence encoding the antibody or the antibody fragment, a vector comprising the nucleotide sequences, an amino acid sequences of the antibodies or the antibody fragments, a method of producing the antibodies or the antibody fragments thereof, and a method of decreasing the agonistic potency of an antibody against DR3 through its binding, are provided.Type: ApplicationFiled: October 8, 2015Publication date: July 6, 2017Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: David MILLS, Kazuma TOMIZUKA, John LAUDENSLAGER, Rinpei NIWA, Mami TSUCHIYA
-
Publication number: 20170166650Abstract: Among N-glycoside-linked sugar chains which are bound to the Fc region of an antibody, sugar chains which are bound to Asn at position 297 relates to the activity and stability of the antibody in blood, but there is a possibility that extra sugar chains bound to the amino acid residues at positions other than 297 have influences upon the antibody constant region-mediated activity and a possibility of causing a problem of uniformity as a therapeutic antibody preparation. Accordingly, among N-glycoside-linked sugar chains which bind to the Fc region of the antibody, a method for controlling extra sugar chains which are bound to Asn residues at positions other than position 297 according to the EU index is required.Type: ApplicationFiled: December 16, 2016Publication date: June 15, 2017Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Rinpei NIWA, Mami TSUCHIYA
-
Patent number: 9675625Abstract: A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.Type: GrantFiled: June 17, 2013Date of Patent: June 13, 2017Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya Shitara, Rinpei Niwa, So Ohta, Yuka Sakai, Junji Kanazawa, Toshihiko Ishii, Shiro Akinaga
-
Patent number: 9556279Abstract: Among N-glycoside-linked sugar chains which are bound to the Fc region of an antibody, sugar chains which are bound to Asn at position 297 relates to the activity and stability of the antibody in blood, but there is a possibility that extra sugar chains bound to the amino acid residues at positions other than 297 have influences upon the antibody constant region-mediated activity and a possibility of causing a problem of uniformity as a therapeutic antibody preparation. Accordingly, among N-glycoside-linked sugar chains which bind to the Fc region of the antibody, a method for controlling extra sugar chains which are bound to Asn residues at positions other than position 297 according to the EU index is required.Type: GrantFiled: March 2, 2011Date of Patent: January 31, 2017Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Rinpei Niwa, Mami Tsuchiya
-
Patent number: 9475886Abstract: The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: GrantFiled: September 30, 2014Date of Patent: October 25, 2016Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya Shitara, Rinpei Niwa, Akito Natsume
-
Publication number: 20160108136Abstract: The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: ApplicationFiled: September 30, 2014Publication date: April 21, 2016Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Kenya SHITARA, Rinpei NIWA, Akito NATSUME
-
Patent number: 8883981Abstract: The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: GrantFiled: July 2, 2010Date of Patent: November 11, 2014Assignee: Kyowa Hakko Kirin Co., LtdInventors: Kenya Shitara, Rinpei Niwa, Akito Natsume
-
Patent number: 8877913Abstract: An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.Type: GrantFiled: January 31, 2013Date of Patent: November 4, 2014Assignee: Kyowa Hakko Kirin Co., LtdInventors: Tomoaki Nakagawa, Sayaka Hori, Rinpei Niwa, Tsuguo Kubota, Kazuhiro Masuda, Kazuyasu Nakamura
-
Publication number: 20140120581Abstract: According to the present invention, a heterodimer protein composition that is composed of a first polypeptide comprising an immunoglobulin heavy chain constant region and a second polypeptide comprising CL-Fc prepared by fusion of an immunoglobulin light chain constant region (CL) and Fc region, and also has a deletion or substitution of Cys residues involved in disulfide bonds between CL and CH1, a purification method of the protein composition thereof, a preparation method of the protein composition thereof, a DNA and a vector encoding the protein composition thereof are providedType: ApplicationFiled: October 4, 2013Publication date: May 1, 2014Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Rinpei NIWA, Mami TSUCHIYA, Takuya MURAKAMI, Yuta TEZUKA
-
Patent number: 8632996Abstract: A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.Type: GrantFiled: June 8, 2012Date of Patent: January 21, 2014Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kenya Shitara, Nobuo Hanai, Emi Shoji, Mikiko Sakurada, Akiko Furuya, Kazuyasu Nakamura, Rinpei Niwa, Kenji Shibata, Motoo Yamasaki